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Abstract
Background Fibrogenic cytokines are recognized as putative
drivers of disease activity and histopathological deterioration
in various kidney diseases.We compared urinary transforming
growth factor β1 (U-TGF-β1) and endothelin 1 (U-ET-1)
levels across body mass index classes and assessed their as-
sociation with the level of urinary angiotensinogen (U-AGT),
a biomarker of intrarenal renin–angiotensin–aldosterone sys-
tem (RAAS).
Methods The was a cross-sectional evaluation of 302 children
aged 8–9 years. Ambulatory blood pressure (BP), insulin re-
sistance (HOMA-IR), aldosterone level and renal function
were evaluated. U-ET-1, U-TGF-β1 and U-AGT levels were
determined by immunoenzymatic methods.
Results Obese children presented with the lowest levels of U-
ET-1 and U-TGF-β1, but the difference was only significant
for U-ET-1. In obese children, the median levels of both U-
ET-1 and U-TGF-β1 tended to increase across tertiles (T1–
T3) of U-AGT (U-ET-1: T1, 19.9 (14.2–26.3); T2, 32.5 (23.3–
141.6); T3, 24.8 (18.7–51.5) ng/g creatinine, p=0.007; U-
TGF-β1: T1, 2.2 (1.8–4.0); T2, 4.3 (2.7–11.7); T3, 4.9 (3.8–
10.1) ng/g creatinine, p=0.004]. In multivariate models, in the
obese group, U-ET-1 was associated with HOMA-IR and al-
dosterone and U-AGT levels, and U-TGF-β1 was associated
with U-AGT levels and 24 h-systolic BP.
Conclusions Whereas the initial hypothesis of higher levels of
urinary fibrogenic cytokines in obese children was not con-
firmed in our study, both TGF-β1 and U-ET-1 levels were
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associated with U-AGT level, which likely reflects an early
interplay between tissue remodeling and RAAS in obesity-
related kidney injury.
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Introduction
The prevalence of obesity has been steadily increasing world-
wide over the past few decades [1, 2]. Obesity has been iden-
tified as a strong, independent and potentially modifiable risk
factor for the development and progression of kidney disease,
both in adults and in children [3, 4]. Several mechanisms are
thought to contribute to this association [5]. Obesity-related
kidney damage is initially characterized by hyperfiltration [6]
that later potentiates progressive renal damage, with increased
loss of proteins and cellular remodeling and tubulo-interstitial
fibrosis [7]. In fact, tissue remodeling and fibrosis represent a
common pathway in all kidney diseases and are known to be
associated with the local release of several biologically active
factors [8], such as endothelin-1 (ET-1) and transforming
growth factor beta 1 (TGF-β1).
ET-1 is a potent vasoconstrictor that is expressed in several
kidney cell types and plays a role in the interplay between
interstitial fibrosis and glomerulosclerosis [9, 10]. TGF-β1 is
ubiquitously expressed and is involved in extracellular matrix
remodeling, renal fibrogenesis and nephron loss, thus playing
an important role in the progression of chronic kidney disease
(CKD) [11]. The urinary excretion of both ET-1 (U-ET-1) and
TGF-β1 (U-TGF-β1) reflects their intrarenal production, sug-
gesting that both might be used as markers of tissue damage
severity [12, 13]. In children, the levels of both U-ET-1 and U-
TGF-β1 increase in a wide spectrum of kidney conditions,
such as obstructive uropathies [14], reflux nephropathy [15]
and CKD of different etiologies [16], among others. In addi-
tion, the level of U-TGF-β1 correlates with the degree of renal
interstitial fibrosis [17].
Urinary cytokine levels are also increased in children with
congenital single kidneys, even in early phases of
hyperfiltration when proteinuria and renal insufficiency are
still absent [18]. Since kidney diseases with reduced renal
mass are believed to mimic what happens in obesity,
representing a clinical translation of experimental
hyperfiltration models [7], we hypothesized that levels of uri-
nary cytokines might also be increased in overweight and
obese children. This increase would then reflect some initial
degree of inflammation and renal hemodynamic changes.
ET-1 has been proposed as a regulator of the renal renin–
angiotensin–aldosterone system (RAAS) in the setting of obe-
sity [19, 20]. Renin and angiotensin II may also directly
stimulate the TGF-β1 pathway in the kidney [21], indepen-
dently of renal hemodynamics [22]. Thus, levels of U-ET-1
and U-TGF-β1 might also indicate overactivation of the renal
RAAS. This link between renal production of ET-1 and
TGF-β1 and the intrarenal RAAS has not been described yet
in the setting of childhood obesity. Therefore, our aim was to
compare the levels of U-TGF-β1 and U-ET-1 in normal
weight, overweight and obese children and to assess the asso-
c ia t ion of these ur inary cytokines wi th ur inary
angiotensinogen (U-AGT), a biomarker of the intrarenal
RAAS [23].
Methods
Study design and sample
We conducted a cross-sectional study of children aged 8–
9 years who had been followed since birth in a cohort study
(Generation XXI, Porto-Portugal) [24]. Subjects from the
original cohort were eligible for recruitment to the present
study protocol (ObiKid project) if anthropometric data and a
blood sample had been obtained at the 7-year evaluation (n=
4,590). Our aim was to include a minimum sample of 300
children for the Obikid project’s main objective. Assuming a
35 % dropout rate due to refusal to participate, exclusion
criteria or incomplete information, 463 children were pre-
selected to be consecutively screened according to the date
of their 7-year evaluation. Of these 463 children, 16 could
not be contacted, 32 refused to participate, 23 were unable to
schedule the study visits during the recruitment period and 68
met the exclusion criteria [4 with chronic diseases (genetic,
renal or metabolic), 1 with chronic usage of medication (af-
fecting blood pressure, glucose or lipid metabolism), 51 living
(too) far from the study site and 12 twins]. The remaining 324
participants were enrolled in the study, but 22 were excluded
between August 2013 and August 2014due to the lack of
adequate urine samples for the determination of cytokine
levels, leaving 302 children for the final analysis.
Data collection and definition of variables
Anthropometric measurements were obtained and a general
physical examination was performed according to standard
procedures and as previously reported [25]. Waist circumfer-
ence was indexed to height [waist-to-height ratio). The body
mass index (BMI) was calculated, and BMI-for-age values
were classified according to the World Health Organization
reference data for BMI z-scores into the following categories:
normal weight [≤+1 standard deviation (SD)], overweight
(>1SD and ≤+2SD) and obesity (>2SD) [26]. Body fat per-
centage was assessed by foot-to-foot bioelectrical impedance
analysis (TBF-300; Tanita Corp., Tokyo, Japan).
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Ambulatory BP monitoring (ABPM) for 24 h was per-
formed in all children with a portable non-invasive
oscillometric BP recorder (Spacelabs Healthcare® model
90207; OSI Systems, Hawthorne, CA), in the non-dominant
arm with an appropriate cuff size. A minimum monitoring
duration of 24 h with gaps of <2 h was required for the data
set; 5 sets of readings were excluded from the ABPM analysis
due to insufficient readings. Office BP was evaluated a vali-
dated oscillometric sphygmomanometer (model Elite 92125;
Medel, Parma, Italy), with an adequately sized cuff, in the
right arm, by a trained non-physician interviewer. Three BP
measurements were taken, with a 5-min interval between mea-
surements, and the second and third measurements were av-
eraged for further analysis. Sustained hypertension [27] was
defined as an average systolic BP (SBP) and/or diastolic BP
(DBP) measurement of ≥95th percentile, either during the day
or night on ABPM, according to the reference values [27], a
SBP or DPB load of ≥25%, during either the day or night, and
an office SBP and/or DBP of ≥95th percentile, according to
the American Academy of Pediatrics criteria [28]. When of-
fice BP values were <95th percentile, but the remaining
criteria were verified, the children were classified as present-
ing masked hypertension [27]. The absence of dipping was
considered to be a fall in the mean arterial pressure (MAP)
during nighttime of <10 % of the corresponding daytime
MAP.
Laboratory procedures
For all participants, a random spot urine sample was collected
in the morning and a venous blood sample was collected after
an overnight fast of at least 8 h.
The serum creatinine assay was based on the compensated
Jaffé methods and traceable to an isotope dilution mass spec-
trometry method (Olympus AU 5400 automated analyzer;
Beckman Coulter, Brea, CA). Serum cystatin C was assayed
using a particle-enhanced immunonephelometric assay (N la-
tex Cystatin C; Siemens AG, Erlangen, Germany). The
Zappitelli combined formula was used to estimate glomerular
filtration rate (eGFR) [29]. Aldosterone concentration in se-
rum samples was measured using the Liaison Aldosterone
kit® (DiaSorin Inc., Saluggia, Italy). Insulin resistance was
determined using the homeostasis model assessment index
(HOMA-IR) [30].
Urinary creatinine and albumin were determined by a stan-
dard automated clinical chemistry analyzer (Olympus AU
5400 automated analyzer; Beckman-Coulter). Urine and
blood samples were frozen immediately after collection and
stored in aliquots at −80 °C with no additives until further
processing for the U-ET-1, U-TGF-β1, U-AGT and plasma
(P)-AGT measurements; the samples were not subjected to
freeze–thaw cycles that could interfere with the results. These
measurements were made by the Depar tment of
Pharmacology and Therapeutics of the Faculty of Medicine
of the University of Porto using immunoenzymatic methods
with commercial enzyme-linked immunosorbent assay
(ELISA) kits, according to the protocol provided by the man-
ufacturer with slight modifications for U-ET-1 and U-TGF-β1
quantifications (U-ET-1: Biomedica, Medizinprodukte GmbH
& Co KG, Austria; U-TGF-β1: R&D Systems, Minneapolis,
MN; AGTand U-AGT/P-AGT: Total Angiotensinogen Assay
kit, Immuno-Biological Laboratories, Tokyo, Japan). Briefly,
for quantification of U-ET-1, absorbance values from urine
samples were interpolated in a calibration curve in the range
of 0–2 fmol/ml. For quantification of U-TGF-β1, an ELAST®
ELISA Amplification System (PerkinElmer, Waltham, MA)
was used to amplify the signal generated by the enzyme horse-
radish peroxidase (HRP). Specifically, following incubation
with HRP (and washing) and before the addition of the chro-
mogenic substrate, the ELAST® procedure was performed
using a biotinyl-tyramide solution (1:10) and streptavidin-
HRP solution (1:500). The limit of detection of the U-ET-1
and U-TGF-β1 kits was 0.04 fmol/mL and 3.54 pg/mL, re-
spectively. Samples with levels under this detection limit were
arbitrarily assigned the value 0.02 fmol/mL for U-ET-1 and
1.75 pg/mL for U-TGF-β1. All values obtained from spot
urine samples were expressed as normalized for urinary
creatinine.
Statistical analysis
Standard statistical analysis was performed using IBM SPSS
Statistics for Windows, Version 20.0 (IBM Corp., Armonk,
NY). Data are presented as the mean and SD or, if skewed, as
the median and interquartile range (IQR). U-ET-1 and U-
TGF-β1 had an asymmetric distribution and were
logarithmized (base 10) before the linear regression analyses
to obtain a normal distribution. Linear regression models were
used to identify variables independently associated with U-
ET-1 and U-TGF-β1, using log-transformed values of both
urinary cytokines. A final multivariate model was fitted for
each cytokine, including all of the variables that in the univar-
iate analysis were associated with the cytokine levels at p-
values of <0.25, as well as sex and age (in months). Only
24-h SBP was included in all models, since the inclusion of
both SBP and DBP would introduce collinearity and over-
adjustment. All linear regression models were stratified by
BMI z-score classes because there was a significant interaction
between BMI classes and U-AGT levels.
Results
A total of 302 children with a mean (SD) age of 8.8 (0.2) years
were included in our cross-sectional evaluation. General char-
acteristics, ABPM values and biochemical parameters are
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shown in Table 1, according to classes of BMI (normal
weight, n=159; overweight, n=84; obese, n=59). Overweight
and obese children presented significantly higher values of 24-
h SBP, insulin resistance, high-sensitivity C-reactive protein
(hsCRP), uric acid, plasma creatinine and cystatin C, and low-
er eGFR. No differences were found across groups for the
median blood values of interleukin -6 (IL-6), aldosterone
and P-AGT, for urinary albumin values or for U-AGT
excretion.
Figure 1 depicts the distribution of U-ET-1 and U-TGF-β1
according to BMI classes. For U-ET-1, significant differences
were found between groups, with the highest levels in over-
weight children and the lowest in obese children [normal
weight vs. overweight vs. obesity groups: 27.1 (IQR
19.1–27.1) vs. 33.5 (22.0–52.6) vs. 24.4 (18.3–36.7)
fmol/g creatinine, respectively, p=0.032] The median
levels of U-TGF-β1 were also lowest in obese children
[normal weight vs. overweight vs. obesity groups: 5.4
(IQR 2.7–10.0) vs. 5.1 (3.3–9.4) vs. 3.8 (2.2–7.0) ng/g
creatinine, respectively; p=0.060)]
In the univariate analysis, significant associations were
found between U-ET-1 levels and 24-h SBP and DBP,
HOMA-IR and aldosterone in the normal weight group and
between U-ET-1 levels and HOMA-IR and U-AGT in the
obese group (Table 2). For U-TGF-β1, the only significant
associations were found with U-AGT in both the overweight
and obese groups and with eGFR levels in only the over-
weight group (Table 2). The association of U-AGT and each
Table 1 General anthropometric and clinical characteristics and laboratory parameters of the study subjects according to body mass index z-score
classes
General characteristics World Health Organization BMI z-score classificationa pb
Normal weight (n=159) Overweight (n=84) Obese (n=59)
anthropometric and clinical characteristics
Age (months) 105.1±2.9 105.3±2.7 105.6±2.9 0.519
Male sex 82 (52 %) 42 (50 %) 38 (64 %) 0.176
BMI z-score −0.02±0.73 1.55±0.30 2.67±0.48 <0.001
WHtR (cm/m) 44.7±2.5 50.1±3.2 56.8±4.4 <0.001
% body fat mass 10.7±7.2 19.9±8.0 28.3±9.3 <0.001
24-h Ambulatory blood pressure
24-h SBP (mmHg) 111.1±6.4 113.6±7.1 114.3±8.7 0.004
24-h DBP (mmHg) 66.8±4.1 67.2±5.3 66.6±6.0 0.701
Sustained hypertension/masked hypertensionc 1 (0.6 %)/8 (5.0 %) 3 (3.6 %)/5 (6.0 %) 3 (5.1 %)/6 (10.2 %) –
Absence of dipping 34 (22 %) 28 (33 %) 17 (29 %) 0.143
Blood analytical parameters
HOMA-IR 1.12 (0.84–1.36) 1.34 (1.06–1.84) 1.71 (1.30–2.63) <0.001
hsCRP (mg/L) 0.0 (0.0–0.4) 0.5 (0.2–1.2) 0.7 (0.4–1.7) <0.001
IL-6 (pg/mL) 0.75 (0.75–2.43) 1.60 (0.75–3.00) 1.97 (0.75–2.99) 0.096
Uric acid (mg/dL) 3.48±0.66 3.72±0.71 4.02±0.75 <0.001
Creatinine (mg/dL) 0.43±0.06 0.45±0.06 0.45±0.06 0.005
Cystatin-C (mg/L) 0.64±0.07 0.67±0.08 0.69±0.06 <0.001
eGFR (mL/min/1.73 m2) 138.3±15.7 132.5±16.4 132.0±13.2 0.003
Aldosterone (ng/dL) 9.2 (7.0–13.2) 12.1 (7.3–16.5) 9.7 (8.4–12.9) 0.108
P-AGT (μg/mL) 36.4 (32.4–47.3) 37.0 (32.5–44.2) 38.8 (34.1–44.1) 0.665
Urinary analytical parameters
U-Albumin (mg/g creatinine) 3.8 (2.6–7.2) 3.7 (2.2–7.4) 3.9 (2.3–6.2) 0.874
U-AGT (μg/g creatinine) 5.5 (3.8–7.7) 5.2 (3.2–8.6) 4.8 (2.8–7.8) 0.418
The values are presented as themean±standard deviation (SD) or as themedian with the interquartile range (IQR) in parenthesis, for continuous variables
with and without normal distribution, respectively. Categorical variables are shown as a number (n) with the percentage in parenthesis
BMI, body mass index; WHtR, waist-to-height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model
assessment of insulin resistance; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; eGFR, estimated glomerular filtration rate by combined
Zappitelli formula; P-AGT, plasma angiotensinogen; U-AGT, urinary angiotensinogen
a The BMI z-score classification is according to the World Health Organization criteria [26]
b p values were calculated by the one-way analysis of variance (ANOVA) test or by the Kruskal–Wallis test, respectively
c Sustained hypertension and masked hypertension were defined according to the revised American Heart Association criteria for ABPM interpretation [27]
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of the urinary cytokines was found to be significant in obese
children but not in normal weight children (p for interaction=
0.047 and 0.049 for U-ET-1 and U-TGF-β1, respectively).
The relationship between urinary cytokines and U-AGT, strat-
ified by BMI classes, is shown in Fig. 2. In obese children, the
levels of both U-ET-1 and U-TGF- β1 increased with rising
U-AGT [U-ET-1: 1st tertile (T1), 19.9 (IQR 14.2–26.3); 2nd
tertile (T2), 32.5 (23.3–141.6); 3rd tertile (T3), 24.8 (18.7–
51.5) ng/g creatinine, p=0.007; U-TGF- β1: T1, 2.2 (IQR
1.8–4.0); T2, 4.3 (2.7–1.7); T3, 4.9 (3.8–10.1) ng/g creatinine,
p=0.004].
In the multivariate regression models, in the normal weight
group, the log of U-ET-1 increased significantly with 24-h
SBP [mean increase 0.010 (IQR 0.002–0.019) fmol/g creati-
nine per mmHg; p=0.025] and with HOMA-IR [mean in-
crease 0.109 (IQR 0.010–0.208) fmol/g creatinine per unit;
p=0.031)]. In the obese children, U-ET-1 was independently
associated with HOMA-IR [+0.145 (IQR 0.044–0.246) fmol/
g creatinine per unit; p=0.006], aldosterone [−0.038 (IQR
−0.060 to −0.016) fmol/g creatinine per ng/dL; p=0.001)]
and U-AGT [+0.155 (IQR 0.033–0.277) fmol/g creatinine
per tertile of U-AGT; p=0.014]. In the U-TGF-β1 model, no
significant adjusted associations were found for normal
weight or overweight children, and in obese children the log
of U-TGF-β1 was significantly associated only with U-AGT,
increasing by only 0.162 (IQR 0.046 to 0.278) fmol/g creati-
nine per tertile of U-AGT (p=0.007), and 24-h SBP, increas-
ing by 0.012 (IQR 0.001–0.023) fmol/g creatinine per mmHg
(p=0.029) (Table 3).
Discussion
Our study highlights the possibility that ET-1, TGF-β1 and
renal AGT play interacting roles in obesity-related kidney inju-
ry which have not previously been addressed in healthy young
children. Contrary to our initial hypothesis, the prepubertal
obese children, otherwise healthy, in our study did not have
higher levels of the fibrogenic cytokines ET-1 and TGF-β1 in
their urine, but rather they had the lowest levels. However, in
these obese children we did find significant associations be-
tween the levels of U-ET-1 and U-TGF-β1 and the urinary
excretion of AGT, a marker of intrarenal RAAS activity.
Our initial hypothesis that urinary excretion of fibrogenic
cytokines might be increased in obese children was based on
several indirect findings. Urinary excretion of fibrogenic cy-
tokines has been found to be higher in several kidney diseases
[31–34] and, more specifically, in children with congenital
single kidney disease [35], a clinical setting in which
hyperfiltration occurs, similar to what happens in obesity.
Moreover, a study in adults with essential hypertension found
that those with higher BMI presented higher U-TGF-β1 levels
[36]. One possible explanation for our findings is that the
children of our study are at an early phase of obesity-related
kidney injury, when a still unknown mechanism of regulation
might be operating in an attempt to protect the kidney. Inter-
estingly, U-ET-1 has been suggested as a useful marker of
renal inflammation in the early stages of inflammatory renal
disease—before renal function is affected [31]. Further explo-
rations of the levels of urinary fibrogenic cytokines associated
with obesity and of different pediatric ages might help to clar-
ify the interpretation of our results. Given the lack of previous
studies, we advise that our findings be interpreted cautiously.
A particularly important finding of our study is the positive
association of both U-ET-1 and U-TGF-β1 with U-AGT in
obese children. It is well established that in obesity there is a
chronic overactivation of the fat RAAS [32] and that the in-
creased release of adipose tissue-derived RAAS components
into circulation affects hemodynamic homeostasis and the
intrarenal RAAS itself [33]. U-AGT is a non-invasive marker
of intrarenal RAAS activity [37]. The positive association
between urinary levels of fibrogenic cytokines, which has
Fig. 1 Distribution of urinary endothelin 1 (U-ET-1) and transforming
growth factor beta 1 (TGF-β1) according to classes of body mass index
(BMI; Normal weight, Overweight, Obesity). The normal weight,
overweight and obese group classification is according to the World
Health Organization (WHO) classification for BMI z-score values [26].
The U-ET-1 and U-TGF-β1 data are expressed the median (horizontal
line in box) and interquartile range (IQR: 25th–75th percentiles; upper
and lower limits of box). p values were calculated using the Kruskal–
Wallis test
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been shown to reflect their intrarenal production [30, 36],
and U-AGT potentially underlies a mechanism through
which the RAAS and cytokines regulate each other in obe-
sity. Also, in an experimental model, obesity was found to
be associated with increased angiotensin-converting en-
zyme activity, specifically in the kidney, in an ETA
receptor-dependent manner [38]. Should this renal
RAAS–cytokine interaction be sustained, it would support
a deleterious pathway in which normal cytokine-mediated
tissue repair in response to acute injury would give place to
progressive fibrosis that ultimately causes kidney impair-
ment. Thus, our findings fit into the hypothesis that ET-1
acts as a regulator of the local renal RAAS in the setting of
obesity [38, 39] and that RAAS components directly stim-
ulate the TGF-β1 pathway in the kidney [40]. Taken togeth-
er, our results suggest that even in the early phases of kid-
ney injury inflicted by excessive adipose mass, the associ-
ation between urinary cytokines and intrarenal RAAS may
already exist. Thus, even though the obese children in our
study presented the lowest levels of urinary cytokines,
which, as previously stated, might result from a still un-
known mechanism of regulation operating in early phases
of obesity and obesity-related kidney injury, the fact that an
association with U-AGT existed exclusively in this group
Table 2 Univariate linear regression models for urinary urinary endothelin 1 and urinary transforming growth factor beta 1 in normal weight,
overweight and obese childrena
Univariate linear regression models Normal weight Overweight Obese
Crude β (95 % CI) p Crude β (95 % CI) p Crude β (95 % CI) p
Log U-ET-1 (fmol/g creatinine)
Age (monthw) 0.021 (0.002–0.040) 0.027 −0.008 (−0.037 to 0.021) 0.589 0.021 (−0.017 to 0.058) 0.284
24-h SBP (mmHg) 0.014 (0.006–0.023) 0.001 −0.009 (−0.020 to 0.002) 0.115 −0.002 (−0.015 to 0.010) 0.717
24-h DBP (mmHg) 0.015 (0.002–0.028) 0.029 0.003 (−0.012 to 0.019) 0.656 −0.003 (−0.021 to 0.015) 0.772
HOMA-IR (units) 0.155 (0.056–0.255) 0.002 0.033 (−0.087 to 0.153) 0.588 0.109 (0.017–0.200) 0.021
hsCRP (mg/L) −0.015 (−0.059 to 0.029) 0.503 −0.001 (−0.028 to 0.026) 0.931 −0.014 (−0.067 to 0.039) 0.605
IL-6 (pg/mL) 0.004 (−0.016 to 0.023) 0.690 0.013 (−0.024 to 0.051) 0.483 0.000 (−0.061 to 0.061) 0.991
Uric acid (mg/dL) 0.011 (−0.072 to 0.095) 0.792 −0.021 (−0.133 to 0.090) 0.707 0.063 (−0.083 to 0.208) 0.393
eGFR (mL/min/1.73 m2) 0.003 (0.000–0.007) 0.075 −0.003 (−0.008 to 0.002) 0.194 0.008 (0.000–0.016) 0.062
Aldosterone (ng/dL) −0.014 (−0.024 to −0.003) 0.011 −0.004 (−0.018 to 0.010) 0.540 −0.023 (−0.047 to 0.000) 0.052
P-AGT (per tertile) −0.026 (−0.093 to 0.041) 0.439 0.037 (−0.062 to 0.135) 0.458 0.033 (−0.108 to 0.174) 0.637
U-Albumin (mg/g creatinine) 0.001 (−0.001–0.002) 0.389 0.003 (−0.001 to 0.008) 0.155 0.000 (−0.002 to 0.001) 0.902
U-AGT (per tertile) 0.009 (−0.060 to 0.079) 0.793 −0.050 (−0.150 to 0.049) 0.316 0.131 (0.007–0.254) 0.038
Log U-TGF-β1 (ng/g creatinine) 0.121 (−0.021 to 0.263) 0.093 −0.036 (−0.249 to 0.178) 0.742 0.202 (−0.089 to 0.492) 0.170
Log U-TGF-β1 (ng/g creatinine)
Age (months) −0.034 (−0.054 to −0.014) 0.001 −0.024 (−0.054 to 0.005) 0.104 −0.026 (−0.059 to 0.008) 0.134
24-h SBP (mmHg) −0.001 (−0.011 to 0.008) 0.803 0.004 (−0.007 to 0.016) 0.443 0.009 (−0.002 to 0.020) 0.119
24-h DBP (mmHg) 0.000 (−0.015 to 0.015) 0.989 0.005 (−0.010 to 0.021) 0.496 0.013 (−0.003 to 0.029) 0.114
HOMA-IR (units) −0.044 (−0.155 to 0.066) 0.428 0.022 (−0.102 to 0.145) 0.729 −0.043 (−0.129 to 0.043) 0.321
hsCRP (mg/L) 0.007 (−0.042 to 0.055) 0.791 0.010 (−0.018 to 0.037) 0.487 −0.016 (−0.064 to 0.032) 0.510
IL-6 (pg/mL) −0.009 (−0.032 to 0.013) 0.408 0.008 (−0.031 to 0.046) 0.700 −0.016 (−0.071 to 0.038) 0.556
Uric acid (mg/dL) −0.090 (−0.181 to 0.001) 0.053 −0.091 (−0.204 to 0.021) 0.110 −0.090 (−0.219 to 0.040) 0.171
eGFR (mL/min/1.73 m2) 0.002 (−0.002 to 0.006) 0.233 0.005 (0.000–0.010) 0.045 0.000 (−0.007 to 0.008) 0.894
Aldosterone (ng/dL) −0.006 (−0.018 to 0.006) 0.314 −0.008 (−0.022 to 0.007) 0.288 −0.011 (−0.032 to 0.011) 0.321
P-AGT (per tertile) −0.025 (−0.098 to 0.048) 0.503 0.092 (−0.008 to 0.191) 0.070 −0.012 (−0.139 to 0.115) 0.848
U-Albumin (mg/g creatinine) 0.000 (−0.001 to 0.002) 0.794 0.003 (−0.001 to 0.008) 0.178 0.001 (−0.001 to 0.002) 0.437
U-AGT (per tertile) 0.064 (−0.013 to 0.141) 0.100 0.103 (0.003 to 0.203) 0.043 0.172 (0.065 to 0.280) 0.002
Log U-ET-1 (ng/g creatinine) 0.148 (−0.025 to 0.321) 0.093 −0.037 (−0.263 to 0.188) 0.742 0.163 (−0.072 to 0.397) 0.170
U-ET-1, Urinary endothelin-1; TGF-β1, transforming growth factor beta 1; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated
glomerular filtration rate; hCRP, high sensitivity C-reactive protein
a The values presented are adjusted linear regression coefficients (β) and 95% confidence intervals (CI), estimated by univariate linear regressionmodels
with urinary ET-1 (logarithm base 10) or with urinary TGF-β1 (logarithm base 10) as the dependent variables. The results are presented separately by
BMI z-score classes because the effect of U-AGTon each of the urinary cytokines was found to be significant in obese children but not in normal weight
children (p for interaction=0.047 and 0.049 for urinary ET-1 and TGF-β1, respectively)
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probably represents a point of interaction between these
systems that arises in the setting of obesity and which re-
quires further exploration in future studies. As previously
stated, these findings are novel and have not been previous-
ly tested in human trials with pediatric age subjects,
reinforcing the need for a prudent interpretation of our find-
ings and confirmation in further studies.
The negative association which we observed between U-
ET-1 and serum aldosterone levels is difficult to interpret. It
has been proposed that aldosterone itself may also play a role
Table 3 Multivariate linear regression models for urinary urinary endothelin 1 and urinary transforming growth factor beta 1 in normal weight,
overweight and obese children
Multivariate linear regression models Normal weight Overweight Obese
Adjusted β (95 % CI) p Adjusted β (95 % CI) p Adjusted β (95 % CI) p
Log U-ET-1 (fmol/g creatinine)
24-h SBP (mmHg) 0.010 (0.001–0.019) 0.025 −0.008 (−0.020 to 0.003) 0.163 −0.004 (−0.015 to 0.008) 0.500
HOMA-IR (unit) 0.109 (0.010–0.208) 0.031 0.025 (−0.105 to 0.154) 0.706 0.145 (0.044–0.246) 0.006
eGFR (mL/min/1.73 m2) 0.002 (−0.001 to 0.006) 0.179 −0.004 (−0.009 to 0.001) 0.145 0.005 (−0.002 to 0.012) 0.145
Aldosterone (ng/dL) −0.008 (−0.019 to 0.003) 0.135 −0.010 (−0.025 to 0.005) 0.201 −0.038 (−0.060 to −0.016) 0.001
U-Albumin (mg/g creatinine) 0.001 (−0.001 to 0.002) 0.400 0.004 (−0.001 to 0.009) 0.119 −0.008 (−0.026 to 0.011) 0.409
U-AGT (per tertile) 0.007 (−0.063 to 0.077) 0.846 −0.080 (−0.192 to 0.032) 0.161 0.155 (0.033–0.277) 0.014
Log U-TGF-β1 (ng/g creatinine) 0.145 (−0.007 to 0.296) 0.061 −0.018 (−0.254 to 0.217) 0.877 0.083 (−0.204 to 0.370) 0.564
Log U-TGF-β1 (ng/g creatinine)
24-h SBP (mmHg) 0.002 (−0.008 to 0.012) 0.697 0.007 (−0.004 to 0.019) 0.216 0.012 (0.001–0.023) 0.028
Uric acid (mg/dL) −0.074 (−0.165 to 0.017) 0.111 −0.056 (−0.177 to 0.066) 0.364 −0.085 (−0.216 to 0.047) 0.200
eGFR (mL/min/1.73 m2) 0.001 (−0.003 to 0.005) 0.547 0.003 (−0.002 to 0.008) 0.270 −0.001 (−0.008 to 0.007) 0.853
P-AGT (per tertile) −0.010 (−0.083 to 0.063) 0.783 0.071 (−0.030 to 0.172) 0.165 −0.048 (−0.178 to 0.083) 0.466
U-Albumin (mg/g creatinine) 0.000 (−0.002 to 0.001) 0.908 0.001 (−0.005 to 0.005) 0.910 −0.006 (−0.025 to 0.012) 0.488
U-AGT (per tertile) 0.030 (−0.048 to 0.108) 0.452 0.108 (0.001 to 0.215) 0.048 0.167 (0.050–0.285) 0.006
Log U-ET-1 (ng/g creatinine) 0.143 (−0.038 to 0.324) 0.121 −0.028 (−0.258 to 0.203) 0.812 0.099 (−0.154 to 0.353) 0.435
The values presented are adjusted linear regression coefficients (β) and 95 % confidence intervals (CI), estimated by univariate linear regression models
with U-ET-1 (logarithm base 10) or with U-TGF-β1 (logarithm base 10) as the dependent variables. The U-ET-1 model was adjusted for 24-h SBP,
HOMA-IR, eGFR, aldosterone, U-albumin, U-AGT, log U-TGF-β1, as well as for sex and age (months). The U-TGF-β1 model was adjusted for 24-h
SBP, uric acid, eGFR, P-AGT, U-albumin, U-AGT, log U-ET-1, as well as for sex and age (months). Themodels are presented separately by BMI z-score
classes because the effect of U-AGTon each of the urinary cytokines was found to be significant in obese children but not in normal weight children (p
for interaction=0.047 and 0.049 for urinary ET-1 and TGF-β1, respectively)
SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate
Fig. 2 Distribution of U-ET-1 and U-TGF-β1 by tertiles of urinary
angiotensinogen (U-AGT) separately in the normal weight, overweight
and obesity groups, as classified according to the WHO classification for
body mass index z-score values [26]. The tertiles of urinary AGT (T1,
≤4.08; T2, 4.08–6.69; T3, >6.69) were based on data from all enrolled
participants. The urinary ET-1 and TGF-β1 data are expressed as medians
(horizontal line in box) and IQR (25th–75th percentile; upper and lower
limits of box). p values were calculated using the Kruskal–Wallis test.
*Significant at p<0.01
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in the progression of kidney disease, promoting fibrosis by
stimulation of TGF-β1 [34], but the specific interactions of
aldosterone and ET-1 have been less well explored. In animal
models, aldosterone has been observed to increase intrarenal
ET-1 expression [35] and induce ET-1 release from endothelial
cells, contributing to aldosterone-mediated endothelial dys-
function [39]. We cannot rule out the existence of any number
of confounding variables not considered in our analysis which
could explain our findings, which are at variance with the pre-
viously described associations between ET-1 and aldosterone.
In a genetic study of patients with obesity-related glomeru-
lopathy, Wu et al. [38] found that several genes encoding in-
flammatory cytokines, namely those for TGF-β1, leptin recep-
tors and insulin resistance, were upregulated in the glomeruli,
suggesting that IR may directly contribute to the renal injury
observed in obesity. Our findings of an association between U-
ET-1 and HOMA-IR levels, both in normal weight and obese
children, are in line with the results reported by these authors.
IR is believed to represent an important pathway for the devel-
opment of lesions in obesity-related kidney injury [40].We also
found that both U-ET-1 and TGF-β1 levels were positively
associated with SBP in fully adjusted models. Although ET-1
is known to be involved in the regulation of vascular tone,
being a potent vasoconstrictor peptide released by the endothe-
lium [41], the association of U-ET-1 with BP levels is contro-
versial. Glowinska et al. found higher levels of plasma ET-1 in
both obese and hypertensive children, with an association be-
tween SBP and ET-1 levels in the latter group [37]. However,
other studies evaluating U-ET-1 or U-TGF-β1 failed to find an
association between ET-1 levels and BP [33]. Since ET-1 also
exerts complex effects on renal water and sodium excretion,
depending upon its action on ETA (antinatriuretic) or ETB
(natriuretic) receptors [42, 43], and there appears to be a gender
difference in the renal expression of these receptors [42], the
proportion of girls and boys included in the different studies
conducted to date is likely to have affected the results.
We acknowledge a number of important limitations to our
study, the most important of which is likely our sole reliance
on U-AGT levels as a marker of intrarenal RAAS and on the
levels of P-AGT and serum aldosterone as components of the
systemic RAAS. It would be important to integrate our find-
ings with other RAAS measurements, as well as with mea-
surements of other cytokines already recognized as having a
role in obesity-related kidney injury. The determination of
fibrogenic cytokine levels in random urine samples may also
be a limitation of our study, since the representativeness of the
excretion of these markers requires 24-h urine analysis. In our
study, 24-h urine samples were collected and stored at −80 °C
immediately after delivery at the study site, but the levels of
fibrogenic cytokines were not detectable in the pilot samples
analyzed. For this reason measurements in random urine sam-
ples were performed instead. Despite these limitations, our
study is unique and presents innovative results directed
toward trying to elucidate some of the intricate mechanisms
of obesity-triggered kidney impairment. In addition to reveal-
ing an association between urinary fibrogenic cytokines and
U-AGT, thanks to the state-of-the-art cardiovascular evalua-
tion of our sample, which included ABPM, we were able to
show that high BP levels and IR might also be associated with
the expression of fibrogenic cytokines in the kidney.
The association between urinary cytokines and AGT is
particularly relevant, attesting to the existence of an early in-
terplay between the RAAS and the process of tissue remodel-
ing which occurs in the kidneys of obese subjects, even before
puberty. The possibility of following our sample in future
reevaluations of our birth cohort will surely help us to better
understand the mechanisms disclosed in this study and to
track the evolution of kidney impairment in the setting of
obesity throughout their life span.
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